Education
About Us
Working with TipRanks
Follow Us
Bausch + Lomb Corporation (BLCO)
NYSE:BLCO
BLCO Stock Chart & Stats
$15.73
$0.21(1.15%)
At close: 4:00 PM EST
$15.73
$0.21(1.15%)
Day’s Range― - ―
52-Week Range$10.45 - $20.71
Previous CloseN/A
Volume107.99K
Average Volume (3M)512.05K
Market Cap
$5.31B
Enterprise Value$10.03B
Total Cash (Recent Filing)$310.00M
Total Debt (Recent Filing)$4.95B
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Feb 25, 2026EPS Estimate
0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.18
Shares Outstanding354,189,800
10 Day Avg. Volume498,481
30 Day Avg. Volume512,048
Financial Highlights & Ratios
PEG Ratio-0.93
Price to Book (P/B)0.98
Price to Sales (P/S)1.33
P/FCF Ratio-107.69
Enterprise Value/Market Cap1.89
Enterprise Value/Revenue2.02
Enterprise Value/Gross Profit3.39
Enterprise Value/Ebitda19.70
Forecast
1Y Price Target
$15.82Price Target Upside0.57% Upside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)0.53
Revenue Forecast (FY)$5.08B
Bulls Say, Bears Say
Bulls Say
Pipeline GrowthPipeline commentary is anticipated to be positive, suggesting potential growth prospects.
Product DevelopmentThe next-gen LUMIFY Phase 3 trial met all primary and secondary endpoints, which is a positive indicator for future product developments.
Revenue GrowthBausch + Lomb delivered revenue growth in all three segments in 3Q25, showcasing strong performance across Vision Care, Surgical, and Pharmaceuticals.
Bears Say
Investor ConfidenceBLCO's contact lens growth of 6% was slightly below Street expectations of 7%, which may affect investor confidence.
Market SoftnessThere is softness in parts of the world, notably Southeast Asia, impacting the overall growth of the contact lens market.
Separation UncertaintyThere is limited visibility to a full separation from parent Bausch Health, which may hinder near-term growth.
Bausch + Lomb Corporation News
BLCO FAQ
What was Bausch + Lomb Corporation’s price range in the past 12 months?
Bausch + Lomb Corporation lowest stock price was $10.45 and its highest was $20.71 in the past 12 months.
What is Bausch + Lomb Corporation’s market cap?
Bausch + Lomb Corporation’s market cap is $5.31B.
When is Bausch + Lomb Corporation’s upcoming earnings report date?
Bausch + Lomb Corporation’s upcoming earnings report date is Feb 25, 2026 which is in 109 days.
How were Bausch + Lomb Corporation’s earnings last quarter?
Bausch + Lomb Corporation released its earnings results on Oct 29, 2025. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.02.
Is Bausch + Lomb Corporation overvalued?
According to Wall Street analysts Bausch + Lomb Corporation’s price is currently Undervalued.
Does Bausch + Lomb Corporation pay dividends?
Bausch + Lomb Corporation does not currently pay dividends.
What is Bausch + Lomb Corporation’s EPS estimate?
Bausch + Lomb Corporation’s EPS estimate is 0.36.
How many shares outstanding does Bausch + Lomb Corporation have?
Bausch + Lomb Corporation has 354,189,800 shares outstanding.
What happened to Bausch + Lomb Corporation’s price movement after its last earnings report?
Bausch + Lomb Corporation reported an EPS of $0.18 in its last earnings report, beating expectations of $0.16. Following the earnings report the stock price went up 1.776%.
Which hedge fund is a major shareholder of Bausch + Lomb Corporation?
Currently, no hedge funds are holding shares in BLCO
Bausch + Lomb Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$15.82 (0.57% Upside)
$15.82 (0.57% Upside)
Blogger Sentiment
Bullish
BLCO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 569.9K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.59%
12-Months-Change
Fundamentals
Return on Equity
-4.69%
Trailing 12-Months
Asset Growth
2.35%
Trailing 12-Months
Company Description
Bausch + Lomb Corporation
Bausch + Lomb Corporation (BLCO) is a global eye health company that specializes in the development, manufacturing, and marketing of a wide range of products aimed at improving and enhancing vision. The company operates primarily in the ocular health sector, offering products such as contact lenses, lens care products, surgical instruments, and pharmaceuticals for various eye conditions. With a strong focus on innovation, Bausch + Lomb serves both consumers and healthcare professionals, making it a leader in the eye care market.
BLCO Company Deck
BLCO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with strong revenue growth across multiple segments, particularly in Pharmaceuticals and Vision Care. While there are concerns about gross margin and tariff impacts, the company's recovery from the enVista recall and successful cash flow optimization demonstrate resilience and strategic management.View all BLCO earnings summariesBLCO Stock 12 Month Forecast
Average Price Target
$15.82
▲(0.57% Upside)
Technical Analysis
Ownership Overview
0.60% Insiders
0.53% Mutual Funds
6.67% Other Institutional Investors
91.74% Public Companies and
Individual Investors